Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2025 10:31 ET | Source: Equity Insider

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal...
December 06, 2025 08:05 ET | Source: Io Therapeutics, Inc.

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma

Io Therapeutics announced at the American Society of Hematology studies of their RXR agonist IRX4204 in combination with CAR-T cells for multiple myeloma
December 05, 2025 07:44 ET | Source: Research and Markets

Immunotherapy Drugs Research Report 2025: $526.5 Bn Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecast 2024-2034

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
November 27, 2025 09:01 ET | Source: Research and Markets

DLL3-Targeted Immunotherapy Competitor Analysis Report 2025: The Field Still is in Mid-stage Clinical Development Without Clear Leader in the Competition

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "DLL3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 09:00 ET | Source: Research and Markets

B7-H3-Targeted Immunotherapy Competitor Analysis Report 2025: More Than 15 Product Candidates are in Clinical Development, with Several Already in Clinical Phase III

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:58 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 27, 2025 08:54 ET | Source: Research and Markets

Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Competitive Intelligence Report 2025: Launch of the First Tocilizumab Biosimilar Antibodies Highlights the Attractiveness of the Market

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive...
November 27, 2025 08:45 ET | Source: Research and Markets

NaPi2b-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of NaPi2b-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:43 ET | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:42 ET | Source: Research and Markets

STEAP1- and STEAP2-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...